Transurethral Resection of Bladder: Clinical Trials

20 trials of Transurethral Resection of Bladder, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 recruiting, 3 active not recruiting, 3 completed, 3 not yet recruiting. 20 Phase 2, 5 Phase 1, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 220Recruiting 8, Active not recruiting 3, Completed 3, Not yet recruiting 3, Terminated 2, Unknown 1
Phase 15Recruiting 4, Terminated 1
Phase 32Not yet recruiting 1, Recruiting 1

Follow Transurethral Resection of Bladder: new trials by email Literature Review of Transurethral Resection of Bladder trials Research Report on Transurethral Resection of Bladder

Trials (filtered) newest first · largest first

All 20 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Lifileucel (TIL) Therapy After PD-1 Blockade Failure in Kidney Cancer
Cyclophosphamide, Fludarabine, Aldesleukin (IL-2) - Kidney Cancers, Renal Cell Carcinoma (Kidney Cancer)
Phase 2Not yet recruitingBeth Israel Deaconess Medical Center102027-04-262026-11-09
Response-Guided Bladder Preservation With Trastuzumab Rezetecan, Adebrelimab, and Concurrent Bladder Radiotherapy in HER2-Expressing Muscle-Invasive Bladder Cancer
Trastuzumab Rezetecan, Adebrelimab, Concurrent Bladder Radiotherapy - Muscle-Invasive Bladder Cancer (MIBC)
Phase 2Not yet recruitingTongji Hospital702026-09-012026-10-08
Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial
Intensity-Modulated Radiation Therapy, Volume Modulated Arc Therapy, Radiosensitizing Agent - Muscle Invasive Bladder Carcinoma, Stage III Bladder Cancer AJCC v8
Phase 1 / Phase 2RecruitingUniversity of Washington122026-08-202026-08-25
Bladder-Sparing Treatment With Disitamab Vedotin and Toripalimab With or Without Pelvic Lymph Node Dissection in Bladder Cancer
Disitamab Vedotin (RC48), Toripalimab, Transurethral Resection of Bladder Tumor - Bladder Urothelial Carcinoma, Muscle-invasive Bladder Cancer
Phase 2 / Phase 3Not yet recruitingTianjin Medical University Second Hospital1142026-08-012026-08-10
Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
Biospecimen Collection, Eflornithine, Lumbar Puncture - Anaplastic Oligodendroglioma, Astrocytoma, IDH-Mutant, Grade 3
Phase 1 / Phase 2RecruitingMayo Clinic332026-06-232026-06-24
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Biopsy Procedure, Biospecimen Collection - Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma
Phase 2RecruitingNational Cancer Institute (NCI)442026-05-272026-10-26
DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma
DOC1021, Tumor resection, pIFN (peginterferon alfa-2a) - Refractory Melanoma
Phase 1 / Phase 2RecruitingDiakonos Oncology Corporation352026-04-062026-09-09
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
Biospecimen Collection, Computed Tomography, Cystoscopy - Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8
Phase 2RecruitingNational Cancer Institute (NCI)1112025-11-252026-11-03
NEO-BLAST: Neoadjuvant Therapy for Bladder Cancer Followed by Active Surveillance vs Treatment
Active Surveillance, Control arm - Definitive bladder treatment - Muscle-Invasive Bladder Carcinoma
Phase 2 / Phase 3RecruitingPeter Black6882025-07-282025-07-30
Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer
Enfortumab Vedotin, Pembrolizumab, Intensity Modulated Radiation Therapy (IMRT) - Bladder Cancer, Muscle-Invasive Bladder Carcinoma
Phase 1 / Phase 2RecruitingUniversity of California, San Francisco472025-03-312026-10-01
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
DOC1021, Tumor resection, Temodar (Temozolomide) - Glioblastoma (GBM)
Phase 2RecruitingDiakonos Oncology Corporation1802025-03-172026-07-01
Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma
Biospecimen Collection, Cyclophosphamide, Echocardiography - Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma
Phase 2CompletedUniversity of Kansas Medical Center112023-12-212026-04-30
Comprehensive Bladder Preservation Therapy on Patients With Muscle Invasive Bladder Cancer
Tislelizumab Injection, Transurethral resection of bladder tumor, Adjuvant radiotherapy - Urinary Bladder Neoplasms
Phase 2UnknownFirst Affiliated Hospital Xi'an Jiaotong University652023-02-012022-12-28
Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
Biopsy Procedure, Biospecimen Collection, Computed Tomography - Bladder Flat Urothelial Carcinoma In Situ, Non-Muscle Invasive Bladder Urothelial Carcinoma
Phase 2Active not recruitingNational Cancer Institute (NCI)1612020-03-182026-11-12
Niraparib/TTFields in GBM
Niraparib, Optune, Planned surgical resection - Glioblastoma, Recurrent Glioblastoma
Phase 2Active not recruitingAbramson Cancer Center at Penn Medicine302019-12-302026-01-08
Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing Surgery
Cetuximab, Cetuximab-IRDye 800CW, Tumor resection - Brain Neoplasm, Malignant Glioma
Phase 1 / Phase 2TerminatedEben Rosenthal32016-10-012020-03-31
Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder
Pembrolizumab, Transurethral Resection of Bladder Tumor, Gemcitabine - Muscle-invasive Urothelial Cancer of the Bladder
Phase 2CompletedNYU Langone Health602016-08-112026-09-30
A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection
Proton Therapy, Surgery - Craniopharyngioma
Phase 2Active not recruitingSt. Jude Children's Research Hospital1602016-06-222026-09-22
Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)
Methotrexate, Vinblastine, Doxorubicin - Urothelial Carcinoma of the Bladder
Phase 2CompletedFox Chase Cancer Center782016-02-242026-05-22
Chemoradiation in Locally Advanced Pancreatic Cancer
recombinant interferon alfa, cisplatin, fluorouracil - Pancreatic Cancer
Phase 2TerminatedMasonic Cancer Center, University of Minnesota232005-01-012017-12-28

Conditions studied

Urinary Bladder Neoplasms (7)  ·  Glioblastoma (3)  ·  Brain Neoplasms (2)  ·  Glioma (2)  ·  Melanoma (2)  ·  Astrocytoma (1)  ·  Carcinoma (1)  ·  Carcinoma, Renal Cell (1)  ·  Craniopharyngioma (1)  ·  Kidney Neoplasms (1)  ·  Laryngeal Neoplasms (1)  ·  Lymphoma, Follicular (1)  ·  Mouth Neoplasms (1)  ·  Nasopharyngeal Carcinoma (1)  ·  Oligodendroglioma (1)

Sponsors

National Cancer Institute (NCI) (3)  ·  Diakonos Oncology Corporation (2)  ·  Abramson Cancer Center at Penn Medicine (1)  ·  Beth Israel Deaconess Medical Center (1)  ·  Eben Rosenthal (1)  ·  First Affiliated Hospital Xi'an Jiaotong University (1)  ·  Fox Chase Cancer Center (1)  ·  Masonic Cancer Center, University of Minnesota (1)  ·  Mayo Clinic (1)  ·  NYU Langone Health (1)  ·  Peter Black (1)  ·  St. Jude Children's Research Hospital (1)  ·  Tianjin Medical University Second Hospital (1)  ·  Tongji Hospital (1)  ·  University of California, San Francisco (1)

Countries

United States (16)  ·  China (3)  ·  Canada (1)  ·  Guam (1)  ·  Puerto Rico (1)

Top investigators

David Einstein, MD (1)  ·  Eben Rosenthal, MD (1)  ·  Edward W. Greeno, MD (1)  ·  Gordon Li, MD (1)  ·  Jinhai Fan, MD (1)  ·  Leslie Ballas (1)  ·  Matin Imanguli (1)  ·  Michael E Woods (1)  ·  Minas Economides, MD (1)  ·  Muhammad Umair Mushtaq (1)  ·  Peter Black, MD (1)  ·  Shaogang Wang (1)  ·  T. Martin Ma, MD, PhD (1)  ·  Terence C. Burns, MD, PhD (1)  ·  Thomas E. Merchant, DO, PhD (1)

Results publications

PMID 33607632, PMID 33660142, PMID 39680823, PMID 40343719, PMID 41959823, PMID 42567733

NIH funding

P30CA124435 (1), P30CA168524 (1), U10CA180821 (1), U10CA180888 (1), UM1CA186691 (1)